Alexander R Moschen

List of Publications by Year
in descending order

82	14,691	50170 46	64668 79
papers	citations	h-index	g-index

85	85	85	23644
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology, 2006, 6, 772-783.	10.6	2,618
2	Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52, 1836-1846.	3.6	1,857
3	Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. Journal of Immunology, 2007, 178, 1748-1758.	0.4	780
4	NAFLD and diabetes mellitus. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 32-42.	8.2	687
5	Microbiota and diabetes: an evolving relationship. Gut, 2014, 63, 1513-1521.	6.1	631
6	Inflammatory Mechanisms in the Regulation of Insulin Resistance. Molecular Medicine, 2008, 14, 222-231.	1.9	615
7	The Intestinal Microbiota in Colorectal Cancer. Cancer Cell, 2018, 33, 954-964.	7.7	543
8	Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut, 2018, 67, 891-901.	6.1	458
9	Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. Gastroenterology, 2007, 133, 80-90.	0.6	425
10	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology and Metabolism, 2008, 19, 371-379.	3.1	402
11	IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 185-196.	8.2	312
12	Food, Immunity, and the Microbiome. Gastroenterology, 2015, 148, 1107-1119.	0.6	278
13	Interleukinâ€1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2016, 64, 955-965.	3.6	246
14	Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host and Microbe, 2016, 19, 455-469.	5.1	244
15	Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. Trends in Endocrinology and Metabolism, 2017, 28, 388-397.	3.1	235
16	Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor Â expression. Gut, 2010, 59, 1259-1264.	6.1	214
17	Blockade of receptor activator of nuclear factor-ÎºB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nature Medicine, 2013, 19, 358-363.	15.2	211
18	Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clinical Science, 2008, 114, 275-288.	1.8	204

#	Article	IF	Citations
19	Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. Diabetes, 2017, 66, 347-357.	0.3	199
20	Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology, 2021, 73, 833-842.	3.6	188
21	IL-37 protects against obesity-induced inflammation and insulin resistance. Nature Communications, 2014, 5, 4711.	5.8	186
22	Increased Expression of CCL20 in Human Inflammatory Bowel Disease. Journal of Clinical Immunology, 2004, 24, 74-85.	2.0	174
23	Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 119-125.	1.0	173
24	Adipose and Liver Expression of Interleukin (IL)-1 Family Members in Morbid Obesity and Effects of Weight Loss. Molecular Medicine, 2011, 17, 840-845.	1.9	147
25	Dietary Factors: Major Regulators of the Gut's Microbiota. Gut and Liver, 2012, 6, 411-416.	1.4	146
26	Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends in Endocrinology and Metabolism, 2013, 24, 537-545.	3.1	143
27	Dietary lipids fuel GPX4-restricted enteritis resembling Crohnâ€™s disease. Nature Communications, 2020, 11, 1775.	5.8	143
28	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. Journal of Hepatology, 2009, 51, 765-777.	1.8	136
29	Liverâ€“Microbiome Axis in Health and Disease. Trends in Immunology, 2018, 39, 712-723.	2.9	130
30	Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders. Current Pharmaceutical Design, 2010, 16, 1913-1920.	0.9	116
31	How to modulate inflammatory cytokines in liver diseases. Liver International, 2006, 26, 1029-1039.	1.9	114
32	NAD metabolism fuels human and mouse intestinal inflammation. Gut, 2018, 67, 1813-1823.	6.1	104
33	The RANKL/OPG system and bone mineral density in patients with chronic liver disease. Journal of Hepatology, 2005, 43, 973-983.	1.8	100
34	Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. Journal of Hepatology, 2013, 59, 1315-1322.	1.8	92
35	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. Cell Metabolism, 2014, 20, 787-798.	7.2	92
36	Adiponectin and its receptors in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 929-936.	1.8	90

#	Article	IF	Citations
37	Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. Journal of Hepatology, 2006, 44, 537-543.	1.8	88
38	Pathways of liver injury in alcoholic liver disease. Journal of Hepatology, 2011, 55, 1159-1161.	1.8	83
39	Interleukinâ€32: A new proinflammatory cytokine involved in hepatitis C virusâ€related liver inflammation and fibrosis. Hepatology, 2011, 53, 1819-1829.	3.6	79
40	Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology, 2008, 213, 779-787.	0.8	67
41	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine, 2021, 70, 103539.	2.7	67
42	Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 690, 95-101.	0.4	63
43	Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Canadian Journal of Physiology and Pharmacology, 2013, 91, 867-872.	0.7	60
44	Gut microbiome: a new player in gastrointestinal disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 159-172.	1.4	59
45	Mechanisms behind the link between obesity and gastrointestinal cancers. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 599-610.	1.0	58
46	Lipocalinâ€2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. European Journal of Immunology, 2015, 45, 3073-3086.	1.6	53
47	Heterogeneity of fibrosis patterns in nonâ€alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 2013, 33, 624-632.	1.9	48
48	Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. Frontiers in Immunology, 2019, 10, 1070.	2.2	47
49	Visceral Adipose Tissue Attacks Beyond the Liver: Esophagogastric Junction as a New Target. Gastroenterology, 2010, 139, 1823-1826.	0.6	41
50	Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2â€"a Comparative Study. Journal of Crohn's and Colitis, 2021, 15, 43-54.	0.6	40
51	IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation. Journal of Hepatology, 2011, 55, 960-962.	1.8	34
52	Adipocytokines and Hepatocellular Carcinoma. Digestive Diseases, 2012, 30, 508-513.	0.8	33
53	Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visceral Medicine, 2016, 32, 329-334.	0.5	32
54	Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2974-2984.	1.8	24

#	Article	IF	Citations
55	Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis. Gut, 2018, 67, 1434-1444.	6.1	21
56	A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. Hepatology, 2011, 54, 675-686.	3.6	20
57	Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. Liver International, 2020, 40, 1610-1619.	1.9	20
58	Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. Leukemia, 2020, 34, 1885-1897.	3.3	17
59	Ethanolâ€mediated suppression of <scp>IL</scp>â€37 licenses alcoholic liver disease. Liver International, 2018, 38, 1095-1101.	1.9	16
60	Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 620-625.	1.3	15
61	The role of lipocalinâ€2 in liver regeneration. Liver International, 2015, 35, 1195-1202.	1.9	14
62	Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. Npj Vaccines, 2022, 7, 22.	2.9	14
63	Uterine microbiota plasticity during the menstrual cycle: Differences between healthy controls and patients with recurrent miscarriage or implantation failure. Journal of Reproductive Immunology, 2022, 151, 103634.	0.8	14
64	Suppression ofÂinterleukin-17 byÂtype I interferons: aÂcontributing factor inÂvirus-induced immunosuppression?. European Cytokine Network, 2009, 20, 001-006.	1.1	13
65	Weight loss induced by bariatric surgery restores adipose tissue <scp>PNPLA</scp>3 expression. Liver International, 2017, 37, 299-306.	1.9	13
66	Weight Loss Induced by Bariatric Surgery Restricts Hepatic GDF15 Expression. Journal of Obesity, 2018, 2018, 1-6.	1.1	13
67	Evolving therapies for non-alcoholic steatohepatitis. Expert Opinion on Drug Discovery, 2014, 9, 687-696.	2.5	12
68	When the genome bluffs: a tandem duplication event during generation of a novel Agmo knockout mouse model fools routine genotyping. Cell and Bioscience, 2021, 11, 54.	2.1	12
69	Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 383-404.	2.3	11
70	The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients. Current Oncology Reports, 2022, 24, 861-874.	1.8	10
71	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 2022, 9, e000853.	1.1	9
72	Relevance ofTNF-Î± gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 155-158.	1.4	6

#	Article	IF	Citations
73	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. Gut, 2021, 70, 585-594.	6.1	6
74	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	0.6	6
75	Lactobacillus reuteriâ€"an old acquaintance takes on a new task in colorectal tumor surveillance. Cancer Cell, 2022, 40, 125-127.	7.7	5
76	How does the microbiome affect liver disease?. Clinical Liver Disease, 2016, 8, 123-126.	1.0	4
77	Gut Microbiome, Obesity, and Metabolic Syndrome. , 2016, , 447-459.		4
78	Gut Microbiome, Obesity and Metabolic Syndrome. , 2015, , 1-14.		2
79	Editorial: Loss of Epithelial Barrier Integrity in Inflammatory Diseases: Cellular Mediators and Therapeutic Targets. Frontiers in Medicine, 2021, 8, 813153.	1.2	2
80	IBD in the time of corona â€" vigilance for immune-mediated diseases. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 529-530.	8.2	1
81	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 2023, 21, 161-167.	1.0	1
82	Adipose Tissue Inflammation. , 2014, , 93-103.		0